We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Low-grade serous ovarian cancer with BRAF<sup>V600E</sup> mutation treated with metronomic chemotherapy -- a case report and literature review.
- Authors
Rozpłoch-Sapa, Maria; Mrowczyk, Patrycja; Kwinta, Łukasz; Łobacz, Mateusz; Potocki, Paweł M.
- Abstract
Introduction. Ovarian cancer (OC) is the leading cause of cancer death worldwide. In Poland, it is the fourth leading cause of death from neoplasms in women. OC is a heterogeneous disease with low-grade cases characterized by a better prognosis, but poor chemosensitivity. Metronomic chemotherapy (MC) may be a beneficial approach. Case presentation. We present a patient with low-grade serous ovarian cancer (LGSOC) with long-term disease control achieved with MC despite being resistant to standard-dose chemotherapy with paclitaxel and carboplatin. Overall survival (OS) of the patient was 65 months. MC was administered most of the time. The patient was treated with two metronomic regimens: topotecan plus cyclophosphamide and vinorelbine plus methotrexate, both in combination with hormone therapy. The cancer was found to harbor the BRAFV600E mutation (v-raf murine sarcoma viral oncogene homolog B1, a valine-to-glutamic acid substitution at position 600), but that did not impact the treatment. Conclusions. LGSOC has distinct features from high-grade serous ovarian cancer (HGSOC). MC may be a valuable option in LGSOC despite being understudied. The BRAFV600E mutation occurs in 2-33% of low-grade serous ovarian tumors. It is a more common finding in LGSOC than in HGSOC. BRAF inhibition in OC may be a new therapeutic option. Some BRAF inhibitors have already been registered for solid tumors with this mutation.
- Subjects
OVARIAN cancer; TUMORS; CANCER chemotherapy; CARBOPLATIN; PACLITAXEL
- Publication
Oncology in Clinical Practice (2450-1654), 2024, Vol 20, Issue 1, p71
- ISSN
2450-1654
- Publication type
Article
- DOI
10.5603/ocp.96964